This Imlygic market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the increasing incidence of melanoma, the rising prevalence of cancer, FDA approval and expanded market access, greater awareness of oncolytic virus therapy, and increased healthcare expenditure.
The projected growth during the forecast period is driven by the increasing demand for targeted therapies, a growing emphasis on combination treatments, rising research and development funding, greater adoption of novel therapeutics, and expanding global market penetration. Key trends expected during this period include the increased use of combination therapies, greater adoption of immunotherapies, a focus on personalized medicine, enhanced investment in oncological research and development, and the evolution of regulatory frameworks.
The increasing prevalence of melanoma is expected to drive the growth of the imlygic market in the coming years. Melanoma, a form of skin cancer that originates in melanocytes, is becoming more common due to factors such as extended sun exposure, the use of tanning beds, and genetic predisposition. Imlygic (talimogene laherparepvec) is an oncolytic viral therapy injected directly into melanoma tumors, designed to promote local tumor destruction and stimulate a systemic anti-tumor immune response. For example, the National Library of Medicine reported in December 2023 that melanoma cases in the EU-27 reached 101,510 in 2022 and are projected to rise to 115,540 by 2040. This rising incidence of melanoma is fueling the growth of the imlygic market.
The global expansion of healthcare infrastructure is another factor contributing to the growth of the imlygic market. Healthcare infrastructure encompasses the facilities, resources, and systems needed to deliver healthcare services. This expansion is driven by an aging population, a rise in chronic diseases, and technological advancements. Robust healthcare systems are essential for supporting the specialized storage, administration, and coordinated delivery of imlygic as an oncolytic therapy. For instance, Cross River Therapy reported in September 2024 that the U.S. pharmaceutical industry generated $550 billion in revenue, with medicine spending expected to increase from $576.9 billion in 2021 to between $605 and $635 billion by 2025. This global expansion of healthcare infrastructure supports the continued growth of the imlygic market.
The increase in funding for cancer research and development is also expected to drive the growth of the imlygic market. Cancer research funding focuses on advancing treatment, prevention, and research initiatives to address the global cancer burden. Factors such as the need for innovative therapies, the growing emphasis on precision medicine, and rising cancer cases contribute to this increase in funding. Greater financial investment accelerates innovation, clinical trials, and awareness, which in turn fosters the adoption of therapies such as imlygic. For example, in June 2024, the National Cancer Institute reported that its funding for cancer research reached $6.8 billion in 2022, including $216 million from the Cures Act funding, reflecting a 5.7% increase or an additional $366.6 million compared to 2021. This rise in research and development funding is bolstering the growth of the imlygic market.
The key player in the imlygic market is Amgen Inc.
North America was the largest region in the imlygic market in 2024. The regions covered in imlygic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the imlygic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Imlygic is a prescription medication designed to treat certain types of cancer. It is an oncolytic viral therapy that utilizes a genetically modified virus to specifically target and destroy cancer cells. Derived from the herpes simplex virus type 1 (HSV-1), Imlygic is approved for the treatment of melanoma lesions that are inoperable.
The primary patient demographics for Imlygic include pediatric and adult patients. Pediatric patients are defined as individuals from birth to 18 years old who are receiving medical care. Imlygic (talimogene laherparepvec) is also explored in clinical trials for specific cancers such as melanoma. It is distributed through various channels, including hospitals, specialty clinics, online pharmacies, and retail pharmacies, for applications such as melanoma treatment, combination therapy, and the management of other cancer types.
The imlygic market research report is one of a series of new reports that provides imlygic market statistics, including the imlygic industry's global market size, regional shares, competitors with a imlygic market share, detailed imlygic market segments, market trends and opportunities, and any further data you may need to thrive in the imlygic industry. This imlygic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The imlygic market consists of sales of imlygic intralesional injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the increasing incidence of melanoma, the rising prevalence of cancer, FDA approval and expanded market access, greater awareness of oncolytic virus therapy, and increased healthcare expenditure.
The projected growth during the forecast period is driven by the increasing demand for targeted therapies, a growing emphasis on combination treatments, rising research and development funding, greater adoption of novel therapeutics, and expanding global market penetration. Key trends expected during this period include the increased use of combination therapies, greater adoption of immunotherapies, a focus on personalized medicine, enhanced investment in oncological research and development, and the evolution of regulatory frameworks.
The increasing prevalence of melanoma is expected to drive the growth of the imlygic market in the coming years. Melanoma, a form of skin cancer that originates in melanocytes, is becoming more common due to factors such as extended sun exposure, the use of tanning beds, and genetic predisposition. Imlygic (talimogene laherparepvec) is an oncolytic viral therapy injected directly into melanoma tumors, designed to promote local tumor destruction and stimulate a systemic anti-tumor immune response. For example, the National Library of Medicine reported in December 2023 that melanoma cases in the EU-27 reached 101,510 in 2022 and are projected to rise to 115,540 by 2040. This rising incidence of melanoma is fueling the growth of the imlygic market.
The global expansion of healthcare infrastructure is another factor contributing to the growth of the imlygic market. Healthcare infrastructure encompasses the facilities, resources, and systems needed to deliver healthcare services. This expansion is driven by an aging population, a rise in chronic diseases, and technological advancements. Robust healthcare systems are essential for supporting the specialized storage, administration, and coordinated delivery of imlygic as an oncolytic therapy. For instance, Cross River Therapy reported in September 2024 that the U.S. pharmaceutical industry generated $550 billion in revenue, with medicine spending expected to increase from $576.9 billion in 2021 to between $605 and $635 billion by 2025. This global expansion of healthcare infrastructure supports the continued growth of the imlygic market.
The increase in funding for cancer research and development is also expected to drive the growth of the imlygic market. Cancer research funding focuses on advancing treatment, prevention, and research initiatives to address the global cancer burden. Factors such as the need for innovative therapies, the growing emphasis on precision medicine, and rising cancer cases contribute to this increase in funding. Greater financial investment accelerates innovation, clinical trials, and awareness, which in turn fosters the adoption of therapies such as imlygic. For example, in June 2024, the National Cancer Institute reported that its funding for cancer research reached $6.8 billion in 2022, including $216 million from the Cures Act funding, reflecting a 5.7% increase or an additional $366.6 million compared to 2021. This rise in research and development funding is bolstering the growth of the imlygic market.
The key player in the imlygic market is Amgen Inc.
North America was the largest region in the imlygic market in 2024. The regions covered in imlygic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the imlygic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Imlygic is a prescription medication designed to treat certain types of cancer. It is an oncolytic viral therapy that utilizes a genetically modified virus to specifically target and destroy cancer cells. Derived from the herpes simplex virus type 1 (HSV-1), Imlygic is approved for the treatment of melanoma lesions that are inoperable.
The primary patient demographics for Imlygic include pediatric and adult patients. Pediatric patients are defined as individuals from birth to 18 years old who are receiving medical care. Imlygic (talimogene laherparepvec) is also explored in clinical trials for specific cancers such as melanoma. It is distributed through various channels, including hospitals, specialty clinics, online pharmacies, and retail pharmacies, for applications such as melanoma treatment, combination therapy, and the management of other cancer types.
The imlygic market research report is one of a series of new reports that provides imlygic market statistics, including the imlygic industry's global market size, regional shares, competitors with a imlygic market share, detailed imlygic market segments, market trends and opportunities, and any further data you may need to thrive in the imlygic industry. This imlygic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The imlygic market consists of sales of imlygic intralesional injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Imlygic Market Characteristics4. Imlygic Market Trends and Strategies5. Imlygic Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Imlygic Pricing Analysis & Forecasts30. Global Imlygic Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Imlygic Market32. Recent Developments in the Imlygic Market
3. Imlygic Market Biologic Drug Characteristics
6. Global Imlygic Growth Analysis and Strategic Analysis Framework
8. Imlygic Market Segmentation
9. Global Imlygic Epidemiology of Clinical Indications
10. Imlygic Market Regional and Country Analysis
11. Asia-Pacific Imlygic Market
12. China Imlygic Market
13. India Imlygic Market
14. Japan Imlygic Market
15. Australia Imlygic Market
16. South Korea Imlygic Market
17. Western Europe Imlygic Market
18. UK Imlygic Market
19. Germany Imlygic Market
20. France Imlygic Market
21. Eastern Europe Imlygic Market
22. North America Imlygic Market
23. USA Imlygic Market
24. Canada Imlygic Market
25. South America Imlygic Market
26. Middle East Imlygic Market
27. Africa Imlygic Market
28. Imlygic Market Competitive Landscape and Company Profiles
29. Global Imlygic Market Pipeline Analysis
33. Imlygic Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Imlygic Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on imlygic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for imlygic? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The imlygic market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Patient Demographics: Pediatric Patients; Adult Patients2) by Distribution Channel: Hospitals; Specialty Clinics; Online Pharmacies; Retail Pharmacies
3) by Application: Melanoma Treatment; Combination Therapy; Other Cancer Types
Key Companies Mentioned: Amgen Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Amgen Inc.
